{"entity":{"id":"nct06873555","kind":"trial","name":"A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of DC05F01 in ovarian cancer and small-cell lung cancer, run by Heronova Pharmaceuticals, now recruiting.","summary":"A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06873555 by Heronova Pharmaceuticals, with 60 participants planned, started 2024-09-11 and due to reach its primary completion in 2027-12. Interventions recorded: DC05F01.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06873555","url":"https://clinicaltrials.gov/study/NCT06873555"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["ovarian","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06873555","phase":"1/2","setting":"Phase Ib/IIa Multicenter, Open-Label Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Profile of DC05F01 in Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors","sponsor":"Heronova Pharmaceuticals","enrolled":60,"outcomes":[]},"route":"/trials/nct06873555/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}]}}